Related Experiment Video
Updated: Aug 26, 2025
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Caspase-1 inhibition improves cognition without significantly altering amyloid and inflammation in aged Alzheimer
Joseph Flores1, Marie-Lyne Fillion1, Andréa C LeBlanc2,3
1Lady Davis Institute for Medical Research at Jewish General Hospital, Montréal, QC, Canada.
Abstract:
Human genetic and animal model studies indicate that brain microglial inflammation is a primary driver of cognitive impairment in Alzheimer Disease (AD). Inflammasome-activated Caspase-1 (Casp1) is associated with both AD microglial inflammation and neuronal degeneration. In mice, Casp1 genetic ablation or VX-765 small molecule inhibition of Casp1 given at onset of cognitive deficits strongly supports the association between microglial inflammation and cognitive impairment. Here, VX-765 significantly improved episodic and spatial memory impairment eight months after the onset of cognitive impairment in aged AD mice with significant amyloid beta peptide (Aβ) accumulation and microglial inflammation. Unexpectedly, while cognitive improvement was associated with dendritic spine density and hippocampal synaptophysin level recovery, VX-765 only slightly decreased Aβ deposition and did not alter biochemically-measured Aβ levels. Furthermore, increased hippocampal Iba1+-microglia, GFAP+-astrocytes, IL-1β, and TNF-α levels were unaltered by VX-765. These results support the hypothesis that neuronal degeneration, not Aβ or microglial inflammation, drives cognitive impairment in AD.
Insights
In Alzheimer Disease (AD), inhibiting Caspase-1 (Casp1) improved memory in mice. This suggests neuronal degeneration, not amyloid plaques or inflammation, drives cognitive decline in AD.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Microglial inflammation in the brain is a key factor in Alzheimer Disease (AD) related cognitive impairment.
- Inflammasome-activated Caspase-1 (Casp1) is implicated in AD's microglial inflammation and neuronal damage.
Purpose of the Study:
- To investigate the role of Caspase-1 (Casp1) inhibition in mitigating cognitive deficits in an Alzheimer Disease (AD) mouse model.
- To determine if targeting Casp1 impacts amyloid-beta (Aβ) deposition and neuroinflammation.
Main Methods:
- Administered VX-765, a Caspase-1 (Casp1) inhibitor, to aged AD mice exhibiting cognitive deficits and Aβ accumulation.
- Assessed cognitive function, dendritic spine density, synaptophysin levels, Aβ deposition, and inflammatory markers (Iba1, GFAP, IL-1β, TNF-α).
Main Results:
- VX-765 treatment significantly improved episodic and spatial memory in aged AD mice.
- Cognitive improvements correlated with restored dendritic spine density and hippocampal synaptophysin, despite minimal changes in Aβ levels.
- Key inflammatory markers and Aβ deposition remained largely unchanged by Casp1 inhibition.
Conclusions:
- Neuronal degeneration, rather than Aβ accumulation or microglial inflammation, appears to be the primary driver of cognitive impairment in Alzheimer Disease (AD).
- Targeting Caspase-1 (Casp1) may offer therapeutic benefits for cognitive function in AD by preserving neuronal integrity.
More Related Videos
07:07Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze
Published on: October 29, 2019
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...